Northern Trust Corp Purchases 10,232 Shares of Checkpoint Therapeutics, Inc. (NASDAQ:CKPT)

Northern Trust Corp grew its position in shares of Checkpoint Therapeutics, Inc. (NASDAQ:CKPT) by 16.4% during the fourth quarter, according to its most recent filing with the Securities and Exchange Commission (SEC). The fund owned 72,563 shares of the company’s stock after buying an additional 10,232 shares during the period. Northern Trust Corp owned 0.15% of Checkpoint Therapeutics worth $232,000 at the end of the most recent reporting period.

A number of other hedge funds and other institutional investors have also bought and sold shares of the business. Geode Capital Management LLC boosted its stake in shares of Checkpoint Therapeutics by 4.1% during the fourth quarter. Geode Capital Management LLC now owns 445,111 shares of the company’s stock valued at $1,425,000 after purchasing an additional 17,460 shares during the period. Gladstone Institutional Advisory LLC boosted its stake in Checkpoint Therapeutics by 75.4% in the 4th quarter. Gladstone Institutional Advisory LLC now owns 61,399 shares of the company’s stock worth $196,000 after purchasing an additional 26,399 shares in the last quarter. Virtu Financial LLC increased its holdings in Checkpoint Therapeutics by 180.5% in the 4th quarter. Virtu Financial LLC now owns 38,157 shares of the company’s stock worth $122,000 after buying an additional 24,552 shares in the last quarter. Raymond James Financial Inc. bought a new position in Checkpoint Therapeutics during the fourth quarter valued at approximately $67,000. Finally, Charles Schwab Investment Management Inc. purchased a new stake in Checkpoint Therapeutics during the fourth quarter valued at $64,000. Institutional investors own 22.00% of the company’s stock.

Checkpoint Therapeutics Price Performance

Shares of NASDAQ CKPT opened at $4.26 on Tuesday. The stock has a market capitalization of $370.71 million, a price-to-earnings ratio of -2.32 and a beta of 1.18. The firm’s 50 day simple moving average is $4.10 and its 200-day simple moving average is $3.68. Checkpoint Therapeutics, Inc. has a 12 month low of $1.80 and a 12 month high of $4.50.

Checkpoint Therapeutics (NASDAQ:CKPT) last issued its quarterly earnings results on Tuesday, May 13th. The company reported ($0.19) EPS for the quarter, missing the consensus estimate of ($0.10) by ($0.09). Analysts anticipate that Checkpoint Therapeutics, Inc. will post -0.94 earnings per share for the current fiscal year.

Insider Activity

In related news, CEO James F. Oliviero III sold 15,090 shares of the company’s stock in a transaction on Wednesday, April 2nd. The stock was sold at an average price of $4.04, for a total transaction of $60,963.60. Following the transaction, the chief executive officer now owns 3,759,929 shares of the company’s stock, valued at $15,190,113.16. This represents a 0.40% decrease in their ownership of the stock. The sale was disclosed in a legal filing with the SEC, which is available at this link. Also, CFO William Garrett Gray sold 12,322 shares of Checkpoint Therapeutics stock in a transaction that occurred on Tuesday, April 1st. The shares were sold at an average price of $4.05, for a total transaction of $49,904.10. Following the sale, the chief financial officer now owns 1,446,322 shares of the company’s stock, valued at approximately $5,857,604.10. The trade was a 0.84% decrease in their ownership of the stock. The disclosure for this sale can be found here. Insiders own 2.10% of the company’s stock.

Wall Street Analysts Forecast Growth

Several equities analysts have recently commented on CKPT shares. HC Wainwright reissued a “neutral” rating and issued a $4.10 target price on shares of Checkpoint Therapeutics in a report on Tuesday, March 11th. Lake Street Capital restated a “hold” rating and set a $4.10 price objective (down previously from $7.00) on shares of Checkpoint Therapeutics in a research report on Monday, March 10th. Finally, D. Boral Capital reaffirmed a “buy” rating and set a $4.80 price objective on shares of Checkpoint Therapeutics in a report on Monday, March 31st.

About Checkpoint Therapeutics

Checkpoint Therapeutics, Inc, a clinical-stage immunotherapy and targeted oncology company, focuses on the acquisition, development, and commercialization of novel treatments for patients with solid tumor cancers in the United States and internationally. The company's lead antibody product candidate is Cosibelimab, which is in Phase 1 clinical trial to treat patients with selected recurrent or metastatic cancers; and CK-302, a product candidate in preclinical trials for hematological malignancies and solid tumors.